| 摘要 |
<p>Provided herein are optimized methods for treating a degenerative muscle disease, which comprise determining the presence, absence or amount of a biomarker associated with the disease after a drug has been administered, and determining whether a subsequent dose of the drug should be maintained, increased or decreased based on the biomarker assessment. Increased levels of certain biomarkers are linked to muscle degenerative diseases (e.g., GM-CSF(CSF2), TNF-alpha or other pro-inflammatory cytokine acting through NF kappa B), and decreased levels of certain biomarkers are linked to the muscle degenerative diseases 9 e.g., particular microRNA (e.g., miRNA-1, miRNA-133, miRNA-206)). Such methods optimize therapeutic efficacy and minimize toxicity associated with a drug. Also provided herein are therapeutics for treating muscle disorders.</p> |
